Entities / Company
Celldex Therapeutics.
American biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Cantor Fitzgerald released a research report on July 25, 2026, trimming the target price for Celldex Therapeutics.Some support6 reports
-
Trump pledged to unleash American oil and gas production.Some support1 report
-
Celldex Therapeutics provided clinical updates on barzolvolimab, including plans to initiate a second Phase III trial for Chronic Inducible Urticaria and release Phase II data for EoE.Speculative1 report
-
Anthony Marucci was appointed as the CEO of Celldex Therapeutics.Some support1 report
-
Celldex Therapeutics and Zacks Medical operated within the biomedical sector and underperformed the broader market index on August 8, 2025.Some support1 report
-
A study determined that barzolvolimab was not a primary driver in the treatment of Eosinophilic Esophagitis.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Celldex Therapeutics this week
News at the entities that move Celldex Therapeutics most-
Cantor Fitzgerald Mentioned togetherThe event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.Moves Celldex Therapeutics
-
Benzinga Mentioned togetherBenzinga reported on price target changes involving Annaly Capital Management.Moves Celldex Therapeutics
-
Iovance Biotherapeutics OperationalIovance Biotherapeutics and CAMP4 Therapeutics are being compared as healthcare companies.Moves Celldex Therapeutics
-
MarketBeat Mentioned togetherMarketBeat reports analyst recommendations and classifies Legrand and nVent Electric as large-cap industrial companies.Moves Celldex Therapeutics
-
Nasdaq Shared contextVMware's stock performance was tracked on the Nasdaq exchange on October 25, 2026.Moves Celldex Therapeutics
-
Morgan Stanley Mentioned togetherBank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.Moves Celldex Therapeutics
Connections
The 6 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial research reports and ratings tracking Celldex Therapeutics.
-
Iovance Biotherapeutics Operational
The evidence places both companies as competitors operating within the mid-cap healthcare market segment.
-
MarketBeat Mentioned together
MarketBeat reports and aggregates consensus stock ratings and analyst recommendations for Celldex Therapeutics.
-
Morgan Stanley Mentioned together
Morgan Stanley provided analyst coverage regarding Celldex Therapeutics' stock.
-
Nasdaq Shared context
Celldex Therapeutics is listed and trades on the Nasdaq exchange.
-
Benzinga Mentioned together
Benzinga reports on Celldex Therapeutics' stock price targets and analyst ratings.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
5 events- Trump pledged to unleash American oil and gas production.
- Celldex Therapeutics provided clinical updates on barzolvolimab, including plans to initiate a second Phase III trial for Chronic Inducible Urticaria and release Phase II data for EoE.
- Anthony Marucci was appointed as the CEO of Celldex Therapeutics.
- Celldex Therapeutics and Zacks Medical operated within the biomedical sector and underperformed the broader market index on August 8, 2025.
- A study determined that barzolvolimab was not a primary driver in the treatment of Eosinophilic Esophagitis.